Swedish Orphan Biovitrum (Sobi) is a Swedish based pharmaceutical company with an international market presence. The product portfolio consists of some 60 orphan and specialty pharmaceuticals. Sobi has an emerging late stage clinical development orphan and specialty pharmaceutical pipe-line.

We have a pan-European commercial organization, an emerging organization in North America, and partners in and the Middle East, Australia and New Zealand. Sobi has a strong business development track-record and compelling product development and manufacturing capabilities. Sobi has access to about 60 orphan or niche specialty pharmaceuticals. Several late stage rare disease clinical development protein pharmaceutical programs and a progressing pre-clinical development pipe-line may provide exciting additional future product portfolio opportunities that can deliver patient and shareholder value. Our focus areas are: hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer and inherited metabolic disorders.

The organization possesses a high level of expertise and resources within all areas of the value chain, from pre-clinical research and development, business development and production to market access, marketing, distribution and customer support. We are about 500 employees.